earnings
confidence high
sentiment neutral
materiality 0.75
Sarepta Q2 net product revenue $328.7M; GAAP operating income $13.3M; narrows FY2026 guidance
Sarepta Therapeutics, Inc.
2026-Q2 EPS reported
$2.99
revenue$1,132,054,000
- Net product revenue $328.7M: PMO $230.6M, ELEVIDYS $98.1M; total revenue $401.3M, down 34% YoY.
- GAAP net loss $4.9M ($0.05 diluted loss); non-GAAP net income $78.6M ($0.64 diluted EPS).
- Narrowed FY2026 net product revenue guidance to $1.2-$1.3B; non-GAAP R&D+SG&A to $800-$850M.
- Appointed Michael Severino, MD, as CEO effective July 28, 2026; Doug Ingram retired.
- Cash, equivalents, restricted cash and investments $945M, up ~$197M in the quarter.